financetom
Business
financetom
/
Business
/
Philips Navigates Tariffs Through Cost Discipline, Reaffirms Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Philips Navigates Tariffs Through Cost Discipline, Reaffirms Outlook
Nov 4, 2025 6:18 AM

On Tuesday, Koninklijke Philips NV ( PHG ) reported third-quarter 2025 adjusted earnings per share of 42 cents (or 0.36 euros), beating the consensus of 37 cents.

The Dutch healthcare technology group reported quarterly sales of $5.03 billion (4.302 billion euros), in line with the consensus.

Comparable sales increased by 3%, driven by growth across all segments. The Diagnosis & Treatment segment recorded 1% growth, Connected Care recorded 5% growth, and Personal Health showed 11% growth.

Also Read: Philips Ultrasound Devices Deemed Adulterated Over Manufacturing And Oversight Lapses

Income from operations decreased to 330 million euros, mainly due to higher amortization, mostly offset by operational improvements.

Adjusted EBITA increased to 531 million, and the margin improved to 12.3%, mainly driven by sales growth, favorable mix effects, and productivity measures, partly offset by higher tariffs.

“We drove strong order intake and accelerated sales growth, with sustained strength in North America. We expanded margin through innovation, focused execution, and cost discipline, remaining firmly on track as we navigate an uncertain macro environment including tariffs,” Roy Jakobs, CEO of Royal Philips, said in a press release on Tuesday.

Philips said cost management and productivity initiatives delivered savings of 222 million in the quarter. Philips will deliver its three-year, 2.5 billion euros productivity program, including 800 million euros of productivity savings in 2025.

Outlook

Philips reiterates full-year 2025 outlook, with comparable sales growth of 1%—3% remaining unchanged.

Adjusted EBITA margin range to be 11.3%-11.8%, now expected toward the upper end of the range.

The company anticipates free cash flow of 200-400 million euros (including the payout of 1.025 billion euros in the first quarter of 2025 from Philips Respironics recall-related medical monitoring and personal injury settlements in the U.S.).

Price Action: PHG stock was trading higher by 3.05% to $28.04 premarket at last check Tuesday.

Read Next:

Amazon, Google Deals Boosted Cipher Mining’s Credibility, Says CEO, But Admits ‘Bias’ Linked To Bitcoin Mining Background

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Frequency Electronics Wins $7 Million Contract to Support Lunar Space Mission
Frequency Electronics Wins $7 Million Contract to Support Lunar Space Mission
Mar 25, 2026
09:31 AM EDT, 03/25/2026 (MT Newswires) -- Frequency Electronics ( FEIM ) said Wednesday it was awarded a roughly $7 million contract to deliver atomic clocks to assist with position, navigation and timing for a lunar space mission. Shares of the company were up more than 2% in early trading Wednesday. ...
Blueprint Expands Capital Markets Capabilities with Acquisition of HUD Lending Platform
Blueprint Expands Capital Markets Capabilities with Acquisition of HUD Lending Platform
Mar 25, 2026
CHICAGO, March 25, 2026 /PRNewswire/ -- Blueprint Healthcare Real Estate Advisors (Blueprint), the leading advisor in healthcare real estate investment sales, is pleased to announce a significant expansion of its Capital Markets practice through the integration of FHA/HUD lending and servicing capabilities, enabled by the acquisition of the FHA/HUD lending platform from MidCap Financial Services, LLC.   This move allows...
Chinese drugmaker Hengrui's quarterly profit misses forecasts amid generic drug business squeeze
Chinese drugmaker Hengrui's quarterly profit misses forecasts amid generic drug business squeeze
Mar 25, 2026
SHANGHAI, March 25 (Reuters) - Jiangsu Hengrui Pharmaceuticals, China's biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear. The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing's centralised bulk buying programmes, which have...
Ex-Google exec Matt Brittin named new BBC boss
Ex-Google exec Matt Brittin named new BBC boss
Mar 25, 2026
LONDON, March 25 (Reuters) - Britain's BBC on Wednesday named former Google executive Matt Brittin as director general, replacing Tim Davie who quit last year. Brittin, who joined Google in 2007 as head of UK and Ireland before becoming EMEA president in 2014 and stepped down in 2024, will take on the role from May 18. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved